lenvatinib + anti-PD-1 antibody

Lenvatinib + anti-PD-1 antibody is a combination therapy being evaluated by Fudan University for the treatment of advanced thyroid cancer. This regimen combines lenvatinib, an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), PDGFRα, KIT, and RET, with an unspecified anti-PD-1 monoclonal antibody, which acts as an immune checkpoint inhibitor. The combination is specifically utilized in a real-world clinical study (NCT06334107) for patients who lack specific targetable mutations (such as BRAF V600E, NTRK, or RET) or for whom other precision therapies are inaccessible. By simultaneously inhibiting tumor angiogenesis and restoring T-cell mediated anti-tumor immunity, the combination aims to improve outcomes in refractory or advanced thyroid malignancies.

Other names

lenvatinib + anti-PD-1 antibody-Fudan University-thyroid cancerlenvatinib plus anti-PD-1 antibodylenvatinib + PD-1 inhibitor